A Phase II, Randomized, Placebo-Controlled, Double Blind, Trial of Safety, Tolerability and Efficacy Study of Topical AKP-11 Administration to Participants with Arthritis.

Akaal Pharma PTY LTD0 个研究点目标入组 100 人开始时间: 2017年8月22日最近更新: 2020年11月30日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方: Akaal Pharma PTY LTD
入组人数: 100

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 75 Years（—）
性别: All

入选标准

•Males or females aged 18-75 years (inclusive) at the time of screening.
•Primary complaint or clinical findings of osteoarthritis (PART A only).
•Primary complaint or clinical findings of inflammatory arthritis (gout, osteoarthritis, rheumatoid arthritis) (PART B only).
•Stable disease in both extent and severity for at least two weeks prior to the commencement of study treatment.
•An average baseline pain score of equal or greater than 4 on a 11-point NRS (0 to 10) Scale over 3 days prior to randomization. All participants will need to score equal or greater than 4 on the 11 point NRS on Day 1
•Baseline Swelling or Tenderness score of equal or greater than 1 prior to randomization.
•Able to provide written informed consent prior to the performance of any study specific procedures.
•BMI between 18.0 and 45.0 kg/m2, inclusive.
•Female subjects of non-childbearing potential, defined as having a documented tubal ligation at least 6 weeks prior to dosing; having had a surgical bilateral oophorectomy (with or without hysterectomy); at least 12 months of spontaneous amenorrhoea with follicle stimulating hormone (FSH) greater than 40 MIU/ml.
•Female participants of child-bearing potential with negative urine pregnancy test at screening and negative urine pregnancy test at check-in (Day 1), AND; Agree to abstinence for the duration of the study and until 4 weeks after dosing with study drug, if this is in line with the usual and preferred lifestyle; OR agree to use condoms plus one other acceptable form of contraception; i.e. intra-uterine device, hormonal contraception (oral, injected or implanted) or a female diaphragm, from screening until 4 weeks after dosing with study drug; OR has only same-sex partners; OR has a vasectomized partner, which should be the sole partner for that participant.
•Male participants with female partners of child-bearing potential must agree to abstinence if this is in line with the usual lifestyle, or to use condoms plus partner use of an acceptable contraceptive (intrauterine device, hormonal contraception such as oral, injected or implanted; or male condom plus female diaphragm or cervical cap) for the duration of the study and until 4 weeks after dosing with study drug.
•Negative test results for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C at the time of screening.
•Negative drug screening test (drugs of abuse; Creatinine control, testing for amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines) result (urine test) at the time of screening. In participants on prescribed opioids, a positive screening test for opioids is allowed
•Participants who are willing and able to comply with all study assessments and adhere to the protocol schedule.

排除标准

•History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations. Current treatment with immunosuppressant agents or systemic corticosteroids.
•Expected change in existing analgesia, and anti-inflammatory therapy.
•Recent history of major joint injury or surgery.
•Major chronic inflammatory disease (e.g Crohn’s disease, SLE) excluding rheumatoid arthritis,
•Congenital or acquired immunodeficiency or cancer prone syndrome.
•Have evidence of drug or alcohol abuse within 6 months prior to screening visits.
•History of malignancy (other than adequately treated skin carcinoma or carcinoma-in-situ of the cervix).
•Treatment with any of the following within 4 weeks prior to the commencement of study treatment and for the duration of the study: immunosuppressant agents (e.g. methotrexate, cyclosporine, azathioprine, thioguanine, prednisone, prednisolone, hydroxyurea or mycophenolate mofetil); biologics.
•Topical treatment on the area to be studied within 2 weeks prior to commencement of study treatment and for the duration of the study, including: topical corticosteroids; topical NSAID or any other topical that in the opinion of the investigator could modify disease activity.
•Have received any investigational research agent or therapeutic biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of Investigational Product.
•Have received an investigational vaccine within 6 months prior to baseline, or a live attenuated vaccine within 60 days prior to baseline, or intend to have a live vaccination during the course of the study (NB killed/inactive vaccines are allowed).
•Have clinical signs of active infection and/or a temperature of greater than 38.0°C at the time of screening. Study entry may be deferred at the discretion of the Principal Investigator.
•Anticipate surgery within the trial period or history of major surgery within 3 months of screening.
•History of hypersensitivity to any other S1P receptor modulator.
•A depot injection or an implant of any drug within 3 months prior to administration of study treatment, with the exception of a contraceptive implant.
•Participants who are unable to return for all scheduled study visits.
•Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, haematological, malignant, immunologic, psychiatric, metabolic or other uncontrolled systemic disease, with the exclusion of arthritis.
•Any clinically significant abnormality at Screening determined by medical history, physical examination, blood chemistry, haematology, urinalysis and an 12-lead- ECG.
•Any other condition that in the opinion of the investigator would render the subject unsuitable for enrolment, or could interfere with the subject participating in and completing the study or would put the participant at risk.

研究者

发起方

Akaal Pharma PTY LTD

相似试验

进行中（未招募）

不适用

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human SubjectsDiabetes - type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus

EUCTR2009-010720-26-HUSirtris Pharmaceuticals, Inc.225

进行中（未招募）

不适用

EUCTR2009-010720-26-BGSirtris Pharmaceuticals, Inc.225

进行中（未招募）

不适用

EUCTR2009-010720-26-GBSirtris Pharmaceuticals, Inc.225

进行中（未招募）

1 期

A study to investigate if CST-103 and CST-107 has an effect on the brain in patients with progressive disease of the nervous system.Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia.MedDRA version: 24.0Level: LLTClassification code 10012284Term: Dementia due to Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10009846Term: Cognitive impairmentSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10067889Term: Dementia with Lewy bodiesSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2020-006067-28-BECuraSen Therapeutics, Inc.40

进行中（未招募）

不适用

EUCTR2009-010720-26-EESirtris Pharmaceuticals, Inc.225